The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users. Taylor Leamey wrote about all things wellness for CNET, specializing in ...
After months of international availability, the Dexcom G7 constant glucose monitor received its FDA clearance to distribute in the US. Ahead of the wide rollout, we got to go hands-on with a demo ...
DexCom stock (NASDAQ: DXCM) currently trades at $73 per share, around 55% below the highs of $163 seen in November 2021. In comparison, Insulet stock (NASDAQ: PODD) saw its stock decline 39% over the ...
The latest price target for DexCom (NASDAQ:DXCM) was reported by Citigroup on May 4, 2026. The analyst firm set a price target for $79.00 expecting DXCM to rise to within 12 months (a possible 28.46% ...
DexCom is a leader in the continuous glucose monitoring (CGM) systems market. They aren't the only kinds of devices that help diabetes patients keep track of their blood glucose levels -- a necessary ...
Dexcom shares sank more than 40% on Friday, their steepest decline ever. The company reported disappointing revenue on Thursday and lowered its full-year guidance. Executives blamed a restructuring of ...
Partnership will enable two-way data flow between Dexcom glucose biosensors and apps and Oura Ring and the Oura App, providing a first-of-its-kind metabolic health management experience Co-marketing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results